GALACTIC-HF 试验:射血分数降低心衰患者的血清镁与结局
GALACTIC-HF 随机双盲试验纳入左室射血分数≤35%的心衰患者,6147例有基线血清镁数据。三组间猝死和室性快速性心律失常发生率无差异。
要点
- 异常血镁水平未增加猝死或室性快速性心律失常风险,不支持常规纠正低镁血症。
核心结论
- 在GALACTIC-HF试验中,10.7%的HFrEF门诊患者存在高镁血症,与正常镁浓度相比主要复合终点风险更高。
- 异常镁水平与猝死或室性快速性心律失常风险升高无关,这些发现不支持常规纠正低镁血症。
研究设计与样本
- GALACTIC-HF为随机、双盲、多中心、事件驱动试验,比较omecamtiv mecarbil与安慰剂在左室射血分数≤35%心衰患者中的疗效与安全性。
- 共6147例门诊患者具有基线血清镁数据,主要终点为首次心衰恶化事件或心血管死亡的复合终点。
主要发现
- 主要复合终点发生率(每100人年)在高镁血症组最高(34.9,95%CI 31.2-39.0),低镁血症组(21.5,19.4-23.8)与正常镁组(20.9,19.9-22.0)相似。
- 主要终点的各组分和全因死亡呈现相似趋势;猝死和室性快速性心律失常发生率在三组间无差异,但高镁血症组心衰恶化死亡风险最高。
关键数值与推荐
- 主要复合终点发生率:高镁血症34.9(95%CI 31.2-39.0)/100人年,低镁血症21.5(19.4-23.8)/100人年,正常镁20.9(19.9-22.0)/100人年。
临床怎么用
- 异常血镁水平未增加猝死或室性快速性心律失常风险,无需以此为依据进行常规干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: The frequency and prognostic significance of abnormalities in serum magnesium concentrations have not been described in a contemporary heart failure (HF) population. The authors evaluated the prognostic significance of magnesium concentrations in patients with HF with reduced ejection fraction (HFrEF) enrolled in GALACTIC-HF trial. METHODS: GALACTIC-HF was a randomized, double-blind, multicentre, event-driven trial that investigated the efficacy and safety of omecamtiv mecarbil compared with placebo in HF patients with left ventricular ejection fraction ≤ 35%. The primary outcome was the composite of a first worsening HF event or cardiovascular death. RESULTS: A total of 6147 outpatients had baseline serum magnesium data. Of these, 1082 (17.6%) had magnesium concentrations below .75 mmol/L, 4410 (71.7%) had concentrations within the normal range, and 655 (10.7%) had concentrations above .95 mmol/L. The incidence rate (per 100 person-years) for the primary composite outcome was highest in patients with hypermagnesaemia (34.9, 95% confidence interval 31.2-39.0), while rates were similar between those with hypomagnesaemia (21.5, 19.4-23.8), and normal magnesium (20.9, 19.9-22.0). Similar trends were observed for the components of the primary outcome and all-cause death. The incidence rate of sudden death and ventricular tachyarrhythmia did not differ among the three magnesium groups, but the risk of death from worsening HF was highest in patients with hypermagnesaemia. CONCLUSIONS: In GALACTIC-HF, 10.7% of outpatients with HFrEF had hypermagnesaemia, which was associated with a higher risk of the primary outcome compared with normal magnesium concentrations. Abnormal magnesium levels were not associated with a higher risk of sudden death or ventricular tachyarrhythmias. These findings do not support routine correction of hypomagnesaemia.
引用
- Chimura, Docherty, Jhund, et al. Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial. Eur Heart J. 2026. PMID: 40886161. doi:10.1093/eurheartj/ehaf706
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。